PF-04995274

DRUG5 trials

Sponsors

Pfizer, University of Oxford

Conditions

Depression, UnipolarHealthyTreatment Resistant Depression

Phase 1

A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers

CompletedNCT01091272

Start: 2010-04-30End: 2010-09-30Updated: 2010-09-20

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers

CompletedNCT01173757

Start: 2010-08-31End: 2010-11-30Updated: 2011-06-01

Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274

CompletedNCT01193062

Start: 2010-09-30End: 2011-01-31Updated: 2018-12-03

PF-04995274 and Emotional Processing in Treatment Resistant Depression

CompletedNCT03515733

University of OxfordDepression, Unipolar, Treatment Resistant Depression

Start: 2018-05-31End: 2022-07-26Updated: 2022-11-04

PF-04995274 and Emotional Processing in Un-medicated Depression

CompletedNCT03516604

University of OxfordDepression, Unipolar

Start: 2018-05-16End: 2022-07-29Updated: 2022-11-03

Related Papers

Early effects of a novel 5-HT<sub>4</sub>R agonist (PF-04995274) and the SSRI citalopram on emotional cognition in unmedicated depression: RESTAND study.

2026-05-28